Mapstone, Mark PHD

Alzheimer's disease (AD) is a major public health crisis for our aging population. People with Down Syndrome (DS) are at high risk for AD and because of their unique biology and provide an unparalleled opportunity to develop biomarkers of preclinical AD. Reliable biomarkers of preclinical AD will enable new options for intervention and promote health for people with DS and in the general population.

Alzheimer’s disease (AD) is a major public health crisis for our aging population. People with Down Syndrome (DS) are at high risk for AD and because of their unique biology and provide an unparalleled opportunity to develop biomarkers of preclinical AD. This proposed pilot project will focus on parents of adults with DS, allowing us to address important questions related to the potential impact of a range of genetic factors on both maternal AD risk and AD risk to their DS offspring.

Alzheimer's disease (AD) is a major public health crisis for our aging population. People with Down Syndrome (DS) are at high risk for AD and because of their unique biology and provide an unparalleled opportunity to develop biomarkers of preclinical AD. Reliable biomarkers of preclinical AD will enable new options for intervention and promote health for people with DS and in the general population.

– no change from original: Alzheimer’s disease (AD) is a major public health crisis for our aging population. People with Down Syndrome (DS) are at high risk for AD and because of their unique biology and provide an unparalleled opportunity to develop biomarkers of preclinical AD. Reliable biomarkers of preclinical AD will enable new options for intervention and promote health for people with DS and in the general population.